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Abstract
Background: The monogenic disease osteogenesis imperfecta (OI) is due to single mutations in
either of the collagen genes ColA1 or ColA2, but within the same family a given mutation is
accompanied by a wide range of disease severity. Although this phenotypic variability implies the
existence of modifier gene variants, genome wide scanning of DNA from OI patients has not been
reported. Promising genome wide marker-independent physical methods for identifying disease-
related loci have lacked robustness for widespread applicability. Therefore we sought to improve
these methods and demonstrate their performance to identify known and novel loci relevant to OI.
Results: We have improved methods for enriching regions of identity-by-descent (IBD) shared
between related, afflicted individuals. The extent of enrichment exceeds 10- to 50-fold for some
loci. The efficiency of the new process is shown by confirmation of the identification of the Col1A2
locus in osteogenesis imperfecta patients from Amish families. Moreover the analysis revealed
additional candidate linkage loci that may harbour modifier genes for OI; a locus on chromosome
1q includes COX-2, a gene implicated in osteogenesis.
Conclusion: Technology for physical enrichment of IBD loci is now robust and applicable for
finding genes for monogenic diseases and genes for complex diseases. The data support the further
investigation of genetic loci other than collagen gene loci to identify genes affecting the clinical
expression of osteogenesis imperfecta. The discrimination of IBD mapping will be enhanced when
the IBD enrichment procedure is coupled with deep resequencing.
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Background
Mapping of regions identical-by-descent (IBD) is a power-
ful method for the identification of genetic loci shared
within families and implicated in disease. Classically, typ-
ing of individual genetic markers throughout the genomes
of the afflicted individuals mapped shared haplotypes and
has been successful in finding loci linked with numerous
monogenic traits [1]. An alternative physical method,
Genomic Mismatch Scanning (GMS) [2], physically com-
pares genomes of two affected individuals, related by a
not too distant common ancestor, and enriches for the
IBD regions they share. Despite its promise, the technique
has not been exploited due to technical complexities.
As GMS offers the potential to avoid certain ambiguities
associated with genotyping and may be applicable to
pools of DNA samples from afflicted, related individuals,
we aimed to improve the technique to reduce its inherent
noise and to render it robust.
As compared with linkage discovery by genotyping, phys-
ical methods based on direct comparison of genomic
sequences would enable more complete access to all IBD
regions of the genome. Such methods rely on the fact that
non-IBD regions are densely polymorphic between two
individuals. A conceptually attractive approach for such a
direct comparison involves the formation of duplex heter-
ohybrid DNA fragments from the DNAs of related indi-
viduals sharing a trait of interest, and then challenging
these fragments with reagents actuated by mispairings in
the heterohybrids. Such reagents may bind to the mis-
matched fragment or may introduce strand breaks to per-
mit separation of hybrid fragments that are not perfectly
complementary from those that are perfectly paired from
the IBD regions. Physical comparison has been success-
fully used with a variety of technologies that exploit the
chemical or structural differences between perfectly
matched and mismatched hybrids. These include chemi-
cal mismatch cleavage [3] and various attempts to harness
proteins that respond to mismatches such as resolvase
[4,5], single-stranded DNA-specific nucleases [6,7], MutS
mismatch binding [8-10] or cleavage by the mismatch-
specific enzymatic activity of E. coli MutS, MutL and
MutH [11]. In addition, transfection of hybrid molecules
into bacteria enables enrichment for perfectly paired frag-
ments via an in vivo process dependent on mismatch
repair activities [12,13].
The use of these mismatch recognition methods has gen-
erally been limited to the analysis of a few targeted frag-
ments, but adapting them to genome-wide analysis is
conceivable. Global treatment of fragments from the
entire genome, however, also requires elimination of
reannealed homohybrid fragments (fragments between
strands of DNA from the same individual formed during
hybridization, including both mismatch-bearing hybrids
formed with one paternal and one maternal strand and
isohybrids comprising strands from the same parent)
whose presence would confound the identification of IBD
DNA. Ford and colleagues[14,15], in presenting the con-
cept of genome-wide enrichment of IBD fragments, intro-
duced the strategy of tagging one genome with methyl
groups, and then using restriction enzymes specific for
either methylated or non-methylated DNA, but inactive
with hemimethylated DNA, to remove homohybrid DNA.
In addition, they suggested using various mismatch-spe-
cific agents, either by immunoprecipitation or by the E.
coli mismatch repair system to eliminate mispaired frag-
ments [12,14]. Subsequently, Nelson et al. [2] described
GMS, a combination of the methylation-dependent
homohybrid elimination method with in vitro cleavage
by the mismatch repair proteins MutS, MutL and MutH,
and digestion by exonuclease III. Application of GMS to
pairs of related yeast strains, including mapping of the
IBD-enriched regions by hybridization to arrayed clones,
correctly identified meiotic recombination crossover
points [2].
Use of GMS with mammalian genomes was demonstrated
by enrichment of microsatellite alleles shared between
related individuals [16,17] and confirmation of loci con-
taining previously documented disease-related genes with
mapping of IBD regions by hybridization to DNA arrays
targeted to the chromosome of the known locus [18] or by
microsatellite allele recovery [19]. Despite the recognition
of the potential of GMS [20,21], the approach has not
been widely exploited, due to a lack of availability of the
mismatch repair proteins, various technical challenges
inherent in a multi-step procedure and the lack of appro-
priate means to map the IBD-enriched DNA. A fundamen-
tal problem has been an apparent lack of appreciation of
the need for a highly efficient process to ensure elimina-
tion of non-identical hybrid fragments. Such residual frag-
ments will hybridize to the DNA features on microarrays
and so increase non-specific noise. Modifications to GMS
and IBD mapping have been reported but the results from
genome wide studies showed a substantial lack of con-
cordance to confirm CEPH family meiotic crossovers [22].
As linkage studies require processing of many samples, an
additional limitation has been the use of reagent volumes
and methods unsuitable to high throughput microtiter
plate-based procedures.
We present here an improved protocol for physical enrich-
ment of IBD regions. The monogenic disease osteogenesis
imperfecta (OI; Brittle Bone Disease) provides a context
for demonstrating that the protocol could correctly iden-
tify a well-established monogenic locus and an opportu-
nity to discover novel loci relevant to OI etiology. OI
includes a heterogeneous group of autosomal dominantBMC Genetics 2009, 10:16 http://www.biomedcentral.com/1471-2156/10/16
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inherited disorders characterized by bone fragility and
other generalized connective tissue abnormalities [23]. As
analysis of locus-specific restriction fragment length poly-
morphisms had shown that nearly all cases of OI segre-
gated with the two collagen genes [24-28], genome-wide
linkage analysis was not perceived as necessary. However,
given the wide variety of clinical expression of OI, it is
possible that variants of modifier genes may also cosegre-
gate with OI [29]. Therefore a genome wide analysis
might detect loci harbouring such genes.
We have implemented an IBD enrichment protocol that
overcomes many of the difficulties of the original GMS
protocol. We report that application of the improved pro-
tocol to DNA from OI patients has correctly identified the
shared IBD locus that includes COL1A2 bearing the dis-
ease-causing mutation and additional loci that may be rel-
evant to OI etiology. The protocol is now suitable for
finding linkage loci in applications ranging from mono-
genic disease to complex multigenic disease.
Results
Overview of IBD enrichment process
The procedure for IBD enrichment can be applied to any
related pair of individuals and is outlined in Figure 1.
Affected relatives may have the same phenotype because
they share a particular set of predisposing alleles inherited
from common ancestral chromosomal regions. The pro-
cedure enriches for loci that, due to patterns of parental
meiotic recombination events, are identical between the
siblings, and thus include the predisposing alleles. The
final IBD-enriched product is generically amplified and
the IBD regions are then mapped by various methods,
such as by hybridization to DNA microarrays or high
throughput sequencing.
Genomic DNA (gDNA) from each individual is cleaved
with restriction enzymes that yield fragments of sufficient
length to ensure a high probability that they will include
common polymorphisms. The two sets of fragments are
tagged in different ways such that homohybrid molecules
with identical tags are targeted for subsequent elimina-
tion, but heterohybrids, with differentially tagged strands,
are conserved. After tagging, the DNAs are mixed, dena-
tured and reannealed to form hybrid fragments of differ-
ent types as shown in Figure 1. Strands from one
individual may reanneal with strands from the same indi-
vidual to generate self-self hybrids (as isohybrids or as
mixed parental hybrids), and with strands from the other
individual to produce heterohybrids, either with strands
of different parental origin (M/P heterohybrids) or with
both strands derived from the same parent (M/M or P/P
heterohybrids). Any hybrid with strands from different
ancestral chromosomes, hence bearing mispairs at poly-
morphic sites, is a target for subsequent enzymatic attack
by MutS, MutL and MutH (LSHase) and exo III. The DNA
that survives the procedures that eliminate self-self
hybrids and mismatch specific enzymatic digestion is
enriched for the perfectly paired IBD DNA.
Necessity for high efficiency of removal of non-specific 
DNA
As shown in Table 1, for any relative pair whose ancestral
chromosomes are not related, at least 75% of the DNA
mass is targeted for removal. With sibling pairs, for a given
locus, depending on the sharing status, the process aims
to eliminate 3/4, 7/8 or all of the DNA fragments from the
locus. This represents a major challenge because system-
atic inefficient removal of unwanted DNA reduces the
Physical IBD enrichment process Figure 1
Physical IBD enrichment process. Genomic DNAs 
(gDNA) are isolated from two related, afflicted individuals 
and digested with a restriction enzyme that leaves Exonucle-
ase III-resistant ends and generates fragments of about 4 Kb. 
DNA fragments are modified (diamonds or ovals) to permit 
discrimination between the individuals, for example by pres-
ence or absence of methylation at GATC sequences. The 
fragments are mixed, denatured and renatured under condi-
tions to favour unique copy reannealing. Non-annealed 
strands and hybrids of strands from the same individual are 
eliminated. Reannealed DNA fragments with one strand from 
each individual are called heterohybrids, which may be per-
fectly paired due to inheritance of both strands from the 
same ancestral sequence or mismatched due to variation 
between different ancestral sequences. Mismatched hetero-
hybrid fragments are removed by LSHase, a nucleolytic cock-
tail of MutL, MutS and MutH, and subsequent digestion by 
Exonuclease III. The resulting IBD-enriched DNA is generi-
cally amplified, labelled and mapped by two-colour hybridiza-
tion to genomic topographic arrays, using the reannealed 
DNA as reference. The process is repeated for other 
afflicted pairs in the same family and in additional families. 
Variations include use of oligonucleotides as discrimination 
tags, reducing the number of steps by combining similar 
intermediate purification procedures, and eventually mapping 
IBD regions by high throughput redundant sequencing, with 
or without amplification.
Genomic DNA
Digest with 6-cutter rest. enz.
Family A
Individual 2
gDNA
Add individual discrimination tags
Denature & anneal unique copy sequences
Remove ssDNA
Reference DNA
1.5 μg 1.5 μg
Amplify Label
Map IBD DNA 
by microarray 
hybridization
Remove self-self hybrids
Remove mismatched DNA
Eliminated fragments
Family A
Individual 1
gDNA
X
X
Non-annealed DNA
Cy-5
Cy-3
X
X
X
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sensitivity of detection of IBD regions. This is because for
any of the procedures used for IBD mapping that measure
the mass of DNA at specific sets of sequence positions,
such as those represented on BAC clone microarrays, a
positive signal at a given position indicating IBD enrich-
ment for some pairs must be compared to the signal for
pairs where there is no sharing at the position. Previous
reports have not addressed a quantitative definition of
this problem.
Therefore we determined the level of efficiency required to
adequately detect IBD enrichment. We express the sensi-
tivity of detecting IBD sharing as a Discrimination Factor
(DF), dependent on the overall efficiency of the removal
of homohybrid and mismatched fragments. For an
expected IBD mass fraction, (I), and a residual surviving
fraction of the DNA that was targeted for removal, r, with
r = 1 - overall efficiency,
The behaviour of this function (Figure 2) for the different
classes of DNA fragments (Table 1) shows that the overall
process efficiency for loci with monoparental IBD sharing
must be at least 90% to achieve a minimum of about two-
fold discrimination, a reasonable goal for microarray
analysis or for real time quantitative PCR. This level of
overall efficiency mandates much higher efficiencies for
the individual sequential steps of the process. Therefore,
we designed various assays, each specific for a different
step, to test and select optimum reaction parameters.
Some of the same assays are also routinely performed
both as periodic quality controls to monitor reagents and
enzyme specific activities and as internal and parallel con-
trols during batch processing of multiple DNA sample
pairs.
Robust enrichment of IBD DNA
To produce adequate yields of reannealed fragments, we
ensured that all restriction digested gDNAs had a consist-
ent range of fragment sizes, indicating intact gDNA. We
optimized several components of the process, notably the
choice and concentration of reagents for reannealing in a
formamide emulsion [14,30,31] and conditioning of the
resin that eliminates fragments resulting from nucleolytic
digestion. Quality control during the process also includes
DF
Ir ( 1I )
r
=
+⋅ − (1)
Table 1: Partition of hybrid fragments after random reannealing of sibling pair DNAs.
Heterohybrid Homohybrid
Maternal or Paternal Maternal/Paternal
IBD Non-Identical
All loci 1/8 1/8 1/4 1/2
Biparental IBD locus 1/4 0 1/4 1/2
Monoparental IBD locus 1/8 1/8 1/4 1/2
Non-identical locus 0 1/4 1/4 1/2
Variation in the distribution of reannealed DNA mass depending on the class of locus sharing. The mass distribution for a monoparental IBD locus 
is the same as that expected for annealing of grandparent and grandchild DNAs.
Discrimination between IBD loci and loci with no sharing as a  function of overall process efficiency Figure 2
Discrimination between IBD loci and loci with no 
sharing as a function of overall process efficiency. The 
Discrimination Factor (DF) is the ratio of a value measured 
when the signal is derived from pairs when the fragments are 
enriched for IBD sharing to the value for pairs with no shar-
ing. The overall process efficiency indicates the extent that 
the process has eliminated homohybrids and non-identical 
heterohybrids. Plots of DF as a function of the efficiency (see 
Equation 1) are shown for biparental sharing (IBD-2, gray) 
and monoparental sharing (IBD-1, black). The ratio of the 
DFs for IBD-2 versus IBD-1 is also shown (dashed).
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monitoring of the DNA concentrations after digestion by
the fragmenting restriction endonuclease, after reanneal-
ing, after the final enrichment process and after generic
amplification to detect any atypical losses or excess yields.
Several steps require DNA purification and/or concentra-
tion and with a view to automation and robust process-
ing, we perform the process entirely in microtiter plates
using ultrafiltration instead of alcohol precipitation. The
number of steps has been significantly reduced.
Using mismatched DNA substrates and perfectly matched
controls, we found protein concentrations and reaction
conditions that would eliminate all measurable mis-
matched DNA. We designed model mismatched DNA
substrates with a GATC density typical for the human
genome (about 1 per 0.5 kb), but with only one mismatch
per 3 kb, to ensure that the enzymatic activities that
remove non-identical DNA were efficient even for
genomic DNA fragments containing a lower than typical
density of SNPs. As shown in Figure 3, elimination of mis-
matched substrates, linear or circular, is dependent on
both the nuclease activity of LSHase and subsequent treat-
ment with exonuclease and a resin that removes the
digested DNA. We titrated the LSHase activity and the exo-
nuclease/resin procedure such that a significant fraction of
the control perfectly paired DNA was also degraded. We
also designed two model substrates as internal quality
controls in each sample. One substrate is a 4 kb duplex
with a single mismatch (MM), and the second is perfectly
matched (PM), but with an additional 1 kb of inserted
sequence. To each hybrid DNA sample, we added
amounts of MM and PM that mimicked single copy gDNA
equivalents. Subsequent evaluation by quantitative PCR
using primers specific for each substrate ensured that in
each sib pair sample all enzymatic functions were suffi-
ciently active to provide adequate discrimination (data
not shown). We also included the MM and PM substrates
as parallel controls at concentrations sufficient to observe
the elimination of the mismatched DNA and conserva-
tion of the control DNA (data not shown).
Discrimination efficiency evaluated by quantitative PCR
To determine the extent of discrimination achieved by the
IBD enrichment process, we performed quantitative PCR
(qPCR) on generically amplified IBD-enriched DNA from
CEPH family grandfather-grandchild and grandmother-
grandchild pairs. Meiotic recombination points in CEPH
family pedigrees have been extensively documented
[32,33] and so provide a high resolution map of expected
IBD regions between related pairs of individuals. Process-
ing CEPH grandparent-grandchild pairs mimics sib pair
analysis in that reannealing produces the same expected
mass distribution of hybrid fragments as for monoparen-
tal IBD loci sharing between sib pairs (Table 1). As a result
of parental meiotic crossing over, the sharing status of
each region for a grandfather-grandchild pair is always the
opposite to that of the grandmother-grandchild pair. Fig-
ure 4 shows that IBD loci can be distinguished from non-
identical loci over a range of copy number concentrations.
Differences in Ct values of up to 4 to 6 cycles between IBD
DNA and non-identical depleted DNA from the two com-
plementary relative pairs indicate Discrimination Factors
ranging from about 16 to 64. Therefore for some frag-
ments, there remains less than 1% of the DNA that is
Evaluation and quality control of LSHase activity Figure 3
Evaluation and quality control of LSHase activity. 
Substrates of 3.1 kb that mimic reannealed hybrid restriction 
fragments, either perfectly complementary (IBD) or with a 
single base pair mismatch (N-Id), and either as covalently 
closed circular (ccc) or linear (lin) forms, were incubated 
with LSHase and/or exo III (exo) and treated with the DAP 
procedure (resin), as indicated. Agarose gels of reaction 
products were stained with ethidium bromide. Lane M – high 
mass ladder, Invitrogen.
Quantitative PCR detects an extensive range of enrichment  of IBD DNA Figure 4
Quantitative PCR detects an extensive range of 
enrichment of IBD DNA. Eight CA microsatellite sites 
were assayed by qPCR using a universal (CA)n-specific probe 
and IBD-enriched DNA from complementary grandparent-
grandchild pairs. Loci 1–4 represent shared loci for the 
grandfather-grandchild pair and loci 5–8 represent shared 
loci for the grandmother-grandchild pair. Ct is the cycle 
number at which a common threshold level of amplification 
was achieved.BMC Genetics 2009, 10:16 http://www.biomedcentral.com/1471-2156/10/16
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expected to be depleted by the process (Equation (1), Fig-
ure 2). Based on results from such qPCR assays, we con-
clude that the IBD enrichment procedure is highly
efficient and that generic amplification of the IBD DNA
adequately conserves copy number differences.
Identification of IBD regions for grandparent-grandchild 
pairs by mapping on BAC microarrays
To map all IBD regions, amplified reannealed hybrid
DNA, labelled with Cy3, and amplified IBD-enriched
DNA, labelled with Cy5, were hybridized to genome-wide
BAC microarrays [34,35]. As described in Methods, after
initial filtering, we calculated ratios of the Cy5-labeled
IBD-enriched DNA signals to the Cy3-labeled reannealed
DNA signals, and normalized the ratios. We standardized
the variance between arrays using the variance of all the
ratios on each array. Figure 5 shows the profiles of the
ratios for complementary grandparent-grandchild pairs.
The performance of an immobilized DNA clone is vali-
dated when its ratio in an IBD-enriched region is signifi-
cantly greater than its ratio when the region represents
non-identical DNA. Regions of sequential clones with
ratios that consistently discriminate the sharing status
between the two pairs correspond to regions where the
grandparent and grandchild share common microsatellite
alleles due to the child's inheritance of the region from the
grandparent. Therefore, parental meiotic crossover loci
identified by microarray mapping of IBD-enriched DNA
are the same as those identified by microsatellite genotyp-
ing.
Such experiments with pairs of known IBD status vali-
dated the enrichment process and the behaviour of immo-
bilized DNA clones. However, due to uneven distribution
of SNPs and different amounts of unique and efficiently
annealable sequence, each clone displays its particular
characteristics, and hence there is a wide variability in the
ratio values between clones. Indeed, as shown in Figure 5,
the ratios for some clones detecting enrichment are simi-
lar to those of other clones detecting depletion. Therefore,
as described in Methods, in subsequent experiments to
discover unknown IBD regions, we standardized the ratios
by mean centering using the variance of the ratios of each
clone obtained from experiments with 150 CEPH sib
pairs.
Application of IBD enrichment and mapping to identify 
monogenic disease loci
Osteogenesis imperfecta patients from four Old Order
Amish families, descended from a single founding couple,
have a single Gly610Cys mutation in COL1A2, and yet
have variable clinical expressivity of the disease. A sample
family pedigree is shown in Figure 6. DNA was available
for 24 patients and we analyzed 42 affected pairs as shown
in Table 2.
In parallel with the affected pairs, 54 independent control
sib-pairs from the CEPH family collection were processed.
No linkage is expected at any locus in this collection and
as shown in Figure 7, none of the clones showed signifi-
cant evidence for linkage at the nominal p-value < 2 × 10-
5. Thus the protocol is not inherently prone to generate
false positive results.
Analysis of the OI family pairs revealed more than 30
peaks of increased IBD sharing with nominal p-values < 2
× 10-5 (Figure 8). However, the analysis of non-independ-
ent pairs from a small number of families descended from
a common founder will increase the observed IBD sharing
between individuals. Therefore, in the context of a mono-
genic disease the genome-wide threshold for significant
Confirmation of known meiotic crossovers Figure 5
Confirmation of known meiotic crossovers. The IBD 
enrichment process was applied to CEPH family grandpar-
ent-grandchild pairs. Amplification, labelling, hybridization 
and data analysis were performed as described in Methods, 
except standardization was by division of the normalized 
ratios by the standard deviation of the ratios of all clones on 
each array. For chromosome 1, the ratio values for the IBD-
enriched DNA (solid lines) are compared with the regions 
where microsatellite genotypes are shared between a grand-
parent and grandchild (dotted lines); grandfather (GF)/child, 
blue and grandmother (GM)/child, red. The arrow indicates a 
meiotic recombination crossover region.
Crossover
GF / Child 
GM / Child 
Microsat.   IBD-enriched
Table 2: Osteogenesis imperfecta relative pairs
Type of pair Number of pairs Expected shared IBD fraction
Sibling 19 0.75
Avuncular 20 0.5
Cousins 3 0.25BMC Genetics 2009, 10:16 http://www.biomedcentral.com/1471-2156/10/16
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linkage is not useful. Some peaks may be linked to specific
traits that segregated only within a single family. We there-
fore considered that the loci more likely to include any
cosegregating genes would be represented by peaks with
clones showing p-values <10-6, for which all pair-wise
tests were informative and furthermore where all clones
showed IBD sharing. By these criteria, there were two
prominent loci on chromosomes 1 and 7 (Figure 8). The
chromosome 1 locus spanned about 6 Mb (180.3 to
186.2 Mb) and although this may represent a chance shar-
ing of IBD within these families associated with some
trait, it is possible that such a locus harbours a gene that is
relevant to the expression of OI. The chromosome 7 locus,
(76.4 to 96.1 Mb) includes Col1A2 at 93.9 Mb. As this is
the gene bearing the OI causative mutation, we conclude
that the IBD enrichment and mapping procedures have
successfully identified the disease locus in these families.
Discussion
Here we have described several critical modifications to a
physical positional cloning process to ensure its reliability
and to reduce noise in the final mapping analysis. We
have recognized a major challenge in applying this meth-
odology, namely that the procedure must eliminate a
large fraction of the reannealed DNA, mainly comprised
of strands derived from different chromosomes and from
potentially confounding self-self isohybrid fragments. We
have formally defined the dependence of the discrimina-
tion of IBD DNA from non-identical DNA as a function of
the efficiency of the process of IBD selection. Therefore,
we designed the procedure to ensure highly efficient and
specific intermediate yields, and included step-specific
quality control assays. Improvements included a reduc-
tion in the number of steps, optimization of reannealing,
and conditioning of a DNA binding resin to render this
key reagent suitably reliable.
Osteogenesis imperfecta, an autosomal dominant disease Figure 6
Osteogenesis imperfecta, an autosomal dominant disease. Pedigree of Amish family A (Coriell) showing individuals 
with osteogenesis imperfecta as filled symbols.
?
Linkage test results for CEPH control population Figure 7
Linkage test results for CEPH control population. Genome-wide IBD sharing with standardized ratios was determined 
as described in Methods. Based on sib pairs from 54 independent families, no clones in chromosomes 1 through 22 surpass the 
threshold of significance at 2 × 10-5 (red line).
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Sharing of IBD regions among individuals from Amish osteogenesis imperfecta families Figure 8
Sharing of IBD regions among individuals from Amish osteogenesis imperfecta families. Genome-wide IBD shar-
ing with standardized ratios was determined as described in Methods.
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The essential component for IBD selection is the enzy-
matic activity that recognizes and hydrolyzes mismatched
DNA fragments. We cloned the three proteins into high
yield overexpression vectors, and with various methods,
including surface plasmon resonance studies, character-
ized their activities and optimized storage and reaction
conditions [36-38]. We over-titrated the enzymatic activi-
ties and other reagents that eliminate unwanted DNA to
provide sufficient discrimination for mapping of IBD
regions.
Because the yield of the IBD enrichment process is low, we
validated a generic amplification method that produced
sufficient DNA for mapping. Deviations in copy number
representation introduced by the amplification method
are not detrimental to the final array ratio determinations
because increases or decreases in copy number of different
fragments are roughly balanced throughout the long BAC
clone sequences and hence in contiguous clones repre-
senting an IBD region. Any clone-specific or sequence-
dependent deviations are expected to be of similar direc-
tion and magnitude in both sample and reference DNAs.
The range of discrimination factors between 1.3 and 4 that
we observed by BAC clone hybridization might be inter-
preted as representing the efficiency of the enrichment
process. However, microarray analysis is subject to
numerous perturbing factors [39] resulting in dynamic
range dampening. To exclude any microarray-related fac-
tors, we assessed discrimination by qPCR and showed that
the process can enrich some IBD fragments at least 10- to
50-fold. Even though numerous hybrid fragments might
escape the steps designed to eliminate non-identical DNA
and so contribute to noise, the improvements we have
introduced to the overall process ensure that the prepon-
derant hybridization signal from the BAC clones is due to
strongly enriched IBD fragments. We have also developed
a related protocol, Genome Hybrid Identity Profiling,
which incorporates these improvements and the use of
self-self hybrid discrimination via ligation of oligonucle-
otide tags; this method enables initial fragmentation of
the gDNA with any restriction enzyme that generates effi-
ciently ligatable termini.
The distinction between Mendelian monogenic disease
and complex polygenic disease has blurred in recent years
[40]; modifier genes may influence the clinical pheno-
types of monogenic conditions [41]. To identify candidate
loci harbouring disease or modifier genes, extended pedi-
grees are particularly useful, as any IBD regions conserved
in most or all of the afflicted individuals are large, whereas
the probability of finding any IBD loci shared among
many distant relatives is small [42,43]. To demonstrate
adequate performance for genome-wide disease gene
mapping, we applied the IBD-enrichment process to Old
Order Amish OI family pairs from an extended pedigree
and successfully identified a chromosome 7 locus con-
taining COL1A2, the gene bearing the mutation responsi-
ble for OI in these families. Another IBD-enriched locus,
mapping to chromosome 1q, includes PTGS2 (COX-2),
located at 184.9 Mb. COX-2 is expressed in a regulated
manner in osteoblasts and is a key regulator in bone for-
mation, interacting with various key proteins of bone
metabolism. Variants of COX-2 might affect the clinical
outcome of collagen mutations and so may be involved in
some of the pleiotropic phenotypes of OI [23,44-46]. The
phenotype of mice homozygous for the Col1A2
Gly610Cys mutation mimics the milder clinical expres-
sion of the mutation in the Amish families, and the phe-
notype of heterozygous mice is inconsistent with
autosomal dominance [47]. As phenotypic severity of the
mutated mice varies substantially depending on the
genetic background [48], these mice would be appropriate
for constructing additional mutations in candidate modi-
fier genes, such as COX-2.
The potential of family-base studies to identify complex
disease genes has yet to be realized; numerous reports
have identified linkage peaks of only suggestive p-values
and loci are often not replicated [49]. Due to modest gene
effects, loci for complex diseases will be difficult to iden-
tify unless at least 1000 families are genotyped [50].
Therefore, much effort has been invested in the genome
wide association approach using high density SNP geno-
typing arrays, and many credible associations have been
described in case-control studies [51]. Nevertheless, in
contrast to linkage analysis, failure to find significant
association in a region, even with high density arrays, can-
not exclude a disease-related gene in the region [50]. Gen-
otyping several hundred thousand markers generates
thousands of significant associations [52], such that the
most significant p-values most likely correspond to gene
regions unrelated to the disease; whereas the rare true
associations are likely to be among the lower ranking p-
values of the significant associations [53]. Hence linkage
studies that whittle the genome to a few regions, followed
by association studies limited to these regions, decrease
the multiple testing burden and the likelihood of false
associations.
Genotypes from high density SNP arrays are also useful
for IBD detection by comparing data from two or more
related individuals to find long runs that contain no gen-
otypes inconsistent with common inheritance from the
same ancestral chromosome, and that exceed some calcu-
lated or simulated cut-off length, thus confidently exclud-
ing runs of random IBS [42,43,54]. This approach has
been applied with small pedigrees to confirm a previously
identified locus for prostate cancer [42], and to identifyBMC Genetics 2009, 10:16 http://www.biomedcentral.com/1471-2156/10/16
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candidate loci for kidney cancer [54]. This novel means to
exploit SNP data, together with the physical method we
present here, provide alternative or complementary strat-
egies for gene hunts in family collections and pedigrees.
By addressing both the set of variants represented on SNP
arrays and additional variants, such as those typically
revealed only by fine mapping of regions of associated
haplotypes, the physical method may detect shorter IBD
regions than the genotyping approach, including regions
that might be excluded as likely IBS, or regions of genuine
IBD runs broken by erroneous genotypes.
To identify small IBD regions, the resolution of the map-
ping method must approach the expected mapping reso-
lution of the physical IBD enrichment procedure. In
addition, genome-wide mapping of IBD-enriched DNA
should preserve the high level of relative enrichment
revealed by qPCR. We expect that next-generation rese-
quencing methods [55] will permit mapping IBD regions
by scoring sequence read depth. Analysis, including geno-
typing of sequenced SNPs, would be restricted to unique
sequences and restriction fragments with some minimum
density of SNPs of high minor allele frequencies, thus
ignoring the sequences that contribute to dampening of
discrimination in microarray analysis. In addition,
sequence selection based on resequencing performance
with pools of IBD-enriched DNA from CEPH family pairs
would generate a genome-wide set of sequences that accu-
rately report IBD sharing. Considering that reannealing to
generate unique sequence hybrids reduces the genomic
representation at least five-fold and that the level of IBD
enrichment for well-behaved sequences is 10- to 50-fold,
very few sequencing runs would be sufficient to obtain a
depth of coverage comparable to the depth that permitted
calling heterozygous SNPs after resequencing an entire
human genome, requiring about 70 runs [56]. Sufficiently
deep coverage may permit distinction between monopa-
rental and biparental sharing in IBD-enriched regions.
Conclusion
We have established a robust process that physically
selects and maps genomic regions that are shared between
family members. The methodological approach, origi-
nally proposed by Ford and colleagues to isolate "inherit-
ance units" [14,15], is now practicable for the
simultaneous processing of several hundred relative pairs
such as sibling pairs under rigorous quality control condi-
tions. The improved process enabled mapping of loci for
a monogenic trait, osteogenesis imperfecta. Using the
physical enrichment process, we have previously reported
the identification of loci for autism, including a locus on
chromosome 16p. With subsequent high density genotyp-
ing in this locus, we found that PRKCB1, protein kinase
beta, is associated with autism [57]. Thus the procedure is
now suitable for enriching for IBD DNA in applications
ranging from monogenic to complex diseases. Coupled
with mature deep resequencing methods to map the IBD-
enriched DNA, the technology will enable increased dis-
crimination that will be required to analyze more dis-
tantly related individuals and cost-efficient pools of IBD-
enriched DNA samples.
Methods
Reagents and DNA
Reagents and suppliers included: restriction endonucle-
ases, Dam methylase and exonuclease III, NE Biolabs;
TempliPhi kit, Amersham; Repli-G WGA kit, Molecular
Staging/Qiagen; SYBR Green, SYBR Gold and PicoGreen,
Molecular Probes/InvitroGen; GenomeHIP reagent com-
ponents including HyFast gDNA reannealing reagent
(HyF), DNA affinity polymer (DAP, a reconditioned
derivative of benzoyl-naphthoyl-DEAE cellulose, Sigma),
DAP buffer, LSHase (a formulation of E. coli MutS, MutL
and MutH), enzyme buffer (EB), a formamide-based array
hybridization buffer (AHB), coverslip removal buffer
(CRB) and stringent wash buffer (SWB), IntegraGen; Mul-
tiscreen filtration plates, Millipore; QIAquick glass-fibre
purification plate, Qiagen; UltraGAPS slides, Corning.
CEPH family genomic DNAs were either prepared from
immortalized tissue culture cells with the Recoverease kit
(Stratagene), a procedure that yields highly intact dialyzed
DNA [58], or obtained from the Coriell repository. BAC
clones were obtained from InvitroGen or from the Central
National de Séquencage, Genoscope (Evry, France). Cori-
ell provides DNA from osteogenesis imperfecta families A,
B, C and D, (for pedigrees and phenotypes, see http://
ccr.coriell.org/nigms/phenotype/oi.html).
DNA quantification
We measured DNA concentrations with PicoGreen in a
384-well fluorescent plate reader using calf thymus DNA
as standard.
Hybrid reannealed DNA
We digested genomic DNA (gDNA) from pairs of relatives
with Pst I and purified and concentrated the digests with
Multiscreen Manu-30 ultrafiltration. We quantified the
purified, digested DNA and verified the expected range of
fragment sizes by agarose electrophoresis. We used Dam
methylase to tag one of the Pst I-digested gDNAs. We
combined 1.5 μg of each of the samples, denatured the
DNA by incubation in 0.15 M NaOH at RT for 10 min,
and neutralized the solution by addition of HyF buffer
and phenol. We reannealed complementary strands by
shaking the emulsion for 18 hours and recovered the
aqueous phase after mixing with chloroform. We immo-
bilized duplex fragments on glass fibre (QIAquick) in the
presence of a chaotropic salt to eliminate non-renatured
single stranded DNA [59]. We eluted the hybrid renaturedBMC Genetics 2009, 10:16 http://www.biomedcentral.com/1471-2156/10/16
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fragments with TE and removed an aliquot for labelling
and hybridization to microarrays.
Enrichment for IBD DNA
We incubated the reannealed hybrid DNA with LSHase in
EB at 37°C for 15 min and heated for 10 min at 65°C. We
incubated the product of the LSHase reaction with Mbo I
and Dpn I for 30 min at 37°C and 10 min at 65°C. Then,
we added exo III, incubated for 30 min at 37°C, added
DAP buffer and treated with DAP to isolate IBD-enriched
duplex DNA free of single-stranded digestion products.
Amplification of IBD-enriched DNA
To amplify the IBD-enriched DNA, we used either Tem-
pliPhi or Repli-G, as recommended by the manufacturers
with minor modifications. We denatured the reannealed
hybrid DNA or the IBD-enriched DNA with NaOH and
amplified for 16 hrs at 30°C. We purified the amplified
products by ultrafiltration and quantified the DNA. The
extent of amplification ranged from about 250- to 2000-
fold, or the equivalent of about 8 to 11 doublings.
Array design
With the aim of choosing 3000 clones with 1 Mb spacing,
we used the program CloneTrek (IntegraGen). Clone
Trek's input includes essential features of each clone and
two parameters, the distance between two clones on the
tiling path and the minimal distance accepted between
two clones. Initially, all clones in the NCBI clone registry
are placed on a tiling path. Clone Trek's iterative algo-
rithm: for each chromosome, while there are clones
whose removal would create acceptable gaps, identify and
remove the least favoured clone. The least favoured clone
has the lowest score with respect to various defined crite-
ria, including FISH data, STS content, sequencing status,
size and mapping status. The arrays had 4 replicates of
2779 clones, including 2266 mapped to a unique
genomic position with the Build 36 assembly (May,
2006). Average spacing was 1.2 Mb and median spacing
0.95 Mb. Duplicate sets of blocks were printed in two
zones in order to maximally separate the two sets of dupli-
cates printed in each block. Various controls including 15
rice BACs were also printed in quadruplicate. Subsequent
versions of the arrays have 5500 clones.
Array printing
We purified BAC DNA using alkaline lysis, filtration and
isopropanol precipitation. We amplified BAC DNA as
described above for amplification of IBD-enriched DNA.
Clone identity was verified by end sequencing of all
clones and restriction digest fingerprinting of some
clones. We checked the fidelity of amplification by verify-
ing that sample BAC fingerprint patterns matched before
and after amplification. We digested 4 to 20 μg of each
amplified BAC with Alu I and purified the digests by ultra-
filtration. The DNA was dried by vacuum centrifugation
and resuspended in 12 μl of 50% DMSO. We printed the
DNA on GAPS2 slides (Corning) with a BioRobotics
MicroGridII arrayer using BioRobotics quill pins; spot
diameters were about 100 microns. We irradiated arrays
with 100 mJ of 254 nm UV light and then baked them at
80°C for two hours. We scanned all slides and examined
the images of auto-fluorescence to identify any pin-spe-
cific problems. We validated the printing batches of about
100 slides by SYBR green staining and hybridization tests
on selected slides.
Mapping of IBD-enriched DNA on microarrays
Amplified reannealed hybrid DNA, labelled with Cy3,
and amplified IBD-enriched DNA, labelled with Cy5,
were hybridized to the BAC microarrays to enable a ratio-
metric analysis [34,35]. Labelling reactions of 30 μl were
for 16 to 18 hours at 37°C with Klenow (exo-) DNA
polymerase (NE Biolabs) and contained 1 μg of DNA, 125
μM random octamers, 120 μM dATP, dGTP, TTP, 60 μM
dCTP and either 50 μM Cy5-dCTP or 50 μM Cy3-dCTP.
We purified the labelled DNA by spun gel filtration
through Sephadex G50 (APB Biotech) in HV45 micro-
plates (Millipore). The specific fluorescence (fluoro-
chromes/Kbp, fl/Kb), of each probe, as determined by
DNA quantification and Cy-specific fluorescence readings
in a fluorescence plate reader using Cy-dCTPs as stand-
ards, ranged from 20 to 50 fl/Kb. We prepared hybridiza-
tion mixes by mixing Cy5- and Cy3-labeled DNA,
concentrating by vacuum centrifugation and resuspend-
ing in 35 μl of AHB containing Cot1 DNA. Array slides
were blocked by incubation in 10% BSA, 0.01% SDS at
37°C for 30 min. We pre-hybridized slides with 40 μl
AHB containing 730 mg/ml salmon sperm DNA at RT for
30 min. We removed about 30 μl of the prehybridization
mix, deposited the hybridization mixes on the arrays, cov-
ered with Hybrislips (Grace) and placed the arrays in indi-
vidual hybridization chambers (Corning) in a water bath
at 42°C for 2 to 3 days. We removed coverslips by gentle
agitation in CRB, rinsed in 2× SSC, soaked in SWB at 45°C
for 10 min, and then briefly rinsed slides in a series of
baths: 0.2× SSC, filtered 0.1× SSC and 70% isopropanol.
We have also tested and validated various commercial
labelling kits, hybridization buffers and alternative proto-
cols, including washing at higher temperatures in the
absence of formamide.
Image and microarray data analysis
Arrays were scanned using an Agilent scanner and fluores-
cent intensities were corrected by subtraction of local
background using GenePix® Pro 5.1. Spots with fluores-
cent signals indicating partial saturation (> 50,000) or sig-
nals less than 2 times the mean of the backgrounds from
all autosomal clones were excluded. A ratio value of IBD-
enriched DNA versus reannealed DNA was determinedBMC Genetics 2009, 10:16 http://www.biomedcentral.com/1471-2156/10/16
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based on the four spot replicates for each clone. Clones
with less than three morphologically acceptable replicates
or with excessive variance of replicate ratios (Var(repli-
cate) - Mean(Var(replicates)) > 2 * Var(Var(replicates))
were eliminated. Median ratios of the replicates for each
clone were computed and data were normalized between
arrays by dividing the ratio of each clone by the mean of
the ratios of all autosomal clones. Unless otherwise noted,
the ratios of each clone were standardized using 150 full
sib pair controls by subtracting the mean of the control
ratios of the clone and dividing by the variance of the con-
trol clone ratios. Only the clones mapped to a unique
genomic position were used in the analysis.
IBD determination and linkage analysis
We determined a moving average (MA) ratio for each
clone. With Rk as the standardized ratio of clone k, di the
physical distance weight for neighbouring clone i (d is
inversely proportional to the distance in Mb from the
clone, using a weighting function based on a normal dis-
tribution), and m the number of flanking clones on each
side of clone k, then  , the MA ratio of clone k is
obtained:
We set m as three, corresponding to a moving window of
seven adjacent clones. As we expect that the status of an
average of 75% of the clones is IBD, a threshold ratio T
was determined such that 75% of the MA-ratios from all
clones and all sib pair controls were greater than T. We set
the IBD status to one for clones with MA-ratios greater
than T and to zero for clones with MA ratios less than T.
After these binary IBD scores were determined for each
clone for each affected relative pair, we then counted the
number of pairs that were IBD at each clone. A region rep-
resented by a clone or a series of consecutive clones is
linked to the trait only if the number of affected pairs that
are IBD for the region exceeds the number of pairs that by
chance could have received copies of the same ancestral
region. The null distribution of chance sharing appropri-
ate for studies with different types of relative pairs was
determined as described [60]; alternative methods to
determine the null distribution may be appropriate for
various experimental designs, including those with inbred
pedigrees [61-64]. To limit the genome-wide probability
of false linkage to 5%, we used the P-value of 2 × 10-5 to
set the pointwise significance threshold for declaration of
significantly increased sharing [65].
Quantitative PCR
PCR amplifications were quantified by real time qPCR,
using a common probe specific for CA microsatellite
repeat sequences [66,67]. Reactions of 25 μl contained 5
ng of amplified IBD-enriched DNA, AmpliTaqGold
buffer, 0.2 mM each dATP, dCTP, dGTP, TTP, 0.4 mM
dUTP, 5 mM MgCl2, 0.005 U/μl uracil-N-DNA glycosy-
lase (Sigma), 0.03 U/μl AmpliTaqGold DNA polymerase
(Roche), 0.2 μM each primer and the probe oligonucle-
otide 5' FAM-(CA)14-TAMRA. Incubations were at 37°C
for 10 min, 95°C for 10 min, followed by 35 cycles at
95°C for 15 sec and 60°C for 1 min.
Availability
The microarray gpr files and three annotation files can be
obtained from http://BMC_Genetics2008.integragen.org.
The file "Osteogenesis_samples.txt" lists the Coriell osteo-
genesis imperfecta samples.
The file "Osteogenesis_relative_pairs.txt" lists the experi-
mental pairs of relatives and the identity codes for the
microarray gpr files.
The file "BAC_clones.txt" lists the clone names and their
chromosomal positions. If it was not possible to confi-
dently position a clone, it is annotated as "Null".
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